Serious adverse events · people without inhibitors
Summary of findings table ‐ Emicizumab 1.5 mg/kg once weekly showed no clear difference in serious adverse events compared with emicizumab 3.0 mg/kg every 2 weeks (moderate certainty).
1 finding from 1 review
Annualized Bleeding Rate (ABR) ‐ All treated bleeds · people without inhibitors
1 finding from 1 review
Annualized joint Bleeding Rate (AjBR) · people without inhibitors
1 finding from 1 review
Annualized spontaneous Bleeding Rate (AsBR) · people without inhibitors
1 finding from 1 review
Proportion with zero bleeds · people without inhibitors
Summary of findings table ‐ Fitusiran prophylaxis probably leads to higher proportion with zero bleeds compared with on‐demand therapy (moderate certainty).
1 finding from 1 review
QoL · people without inhibitors
1 finding from 1 review
All adverse events · people without inhibitors
Summary of findings table ‐ Fitusiran prophylaxis probably leads to higher all adverse events compared with on‐demand therapy (moderate certainty).
1 finding from 1 review
Adverse events ‐ Serious adverse events · people without inhibitors
Summary of findings table ‐ Fitusiran prophylaxis showed no clear difference in adverse events ‐ Serious adverse events compared with on‐demand therapy (moderate certainty).
1 finding from 1 review
QoL · people with inhibitors
1 finding from 1 review
All adverse events · people with inhibitors
Summary of findings table ‐ Emicizumab prophylaxis probably leads to higher all adverse events compared with on‐demand therapy (moderate certainty).
1 finding from 1 review
Serious adverse events · people with inhibitors
Summary of findings table ‐ Emicizumab prophylaxis showed no clear difference in serious adverse events compared with on‐demand therapy (moderate certainty).
1 finding from 1 review
Annualized Bleeding Rate (ABR) ‐ All treated bleeds · people with inhibitors
1 finding from 1 review
Annualized spontaneous Bleeding Rate (AsBR) · people with inhibitors
1 finding from 1 review
Intervention not reported
Total ITI Success · persons with severe haemophilia A and factor inhibitory antibodies
The intervention showed no clear difference in total ITI Success (moderate certainty).
1 finding from 1 review
Intervention not reported
All bleeding events · persons with severe haemophilia A and factor inhibitory antibodies
The intervention may leads to higher all bleeding events (low certainty).
1 finding from 1 review
Intervention not reported
CVAD infections · persons with severe haemophilia A and factor inhibitory antibodies
The intervention showed no clear difference in CVAD infections (moderate certainty).
1 finding from 1 review
Intervention not reported
Severe allergic reaction · persons with severe haemophilia A and factor inhibitory antibodies
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Nephrotic symdrome · persons with severe haemophilia A and factor inhibitory antibodies
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Recurrent VTE · participants with diagnosed DVT
Oral DTIs showed no clear difference in recurrent VTE (7 months) compared with conventional anticoagulation (moderate certainty).
1 finding from 1 review
Recurrent DVT (3 to 12 months) · participants with diagnosed DVT
Oral DTIs showed no clear difference in recurrent DVT (7 months) compared with conventional anticoagulation (moderate certainty).
1 finding from 1 review